Novel treatment approaches are required for relapsed small cell lung cancer (SCLC). Previous studies showed promising activity for lurbinectedin combined with topoisomerase inhibitors in preclinical models of other solid tumors.
Novel treatment approaches are required for relapsed small cell lung cancer (SCLC). Previous studies showed promising activity for lurbinectedin combined with topoisomerase inhibitors in preclinical models of other solid tumors.